Al-Ghamrawy: The Expansion of International Company Investments in Egypt Stems from the Market's Strength and Stability.
Johnson & Johnson: New and Innovative Products are Among Our Priorities for Expansion in the Egyptian Market.
……………………………………………….
Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), met with a delegation from Johnson & Johnson to enhance cooperation with leading global pharmaceutical companies. The meeting aimed to discuss avenues for joint cooperation in training, supporting innovation, and facilitating the availability of new pharmaceutical products, thereby contributing to the development of the Egyptian healthcare sector and achieving Egypt's Vision 2030.
The meeting discussed several key areas, most notably cooperation in training to enhance the efficiency of healthcare professionals, especially in health economics and its role in supporting decision-making. Additionally, they explored mechanisms for the rapid and regular availability of the company's new pharmaceutical innovations, aligning with the state's plans to advance the health sector. The discussion also included the provision of innovative products to enhance the overall health of Egyptian citizens.
During the meeting, Dr. Ali Al-Ghamrawy emphasized that the Authority gives great importance to supporting partnerships with major global companies, with the aim of transferring expertise and technology, and facilitating the registration and availability of new pharmaceutical products, consistent with the state's plans to advance the healthcare sector and achieve pharmaceutical self-sufficiency. He stressed the Authority's commitment to working according to the latest international standards to ensure patients' needs are met and enhancing the competitiveness of the Egyptian market.
Al-Ghamrawy explained that the Egyptian pharmaceutical market possesses significant strength in attracting foreign direct investments, and the substantial regulatory and supervisory development achieved recently has been an important factor in attracting these investments, making Egypt one of the most promising markets in the region.
The Johnson & Johnson delegation expressed their deep appreciation for the leading role played by the Egyptian Drug Authority in developing the pharmaceutical system and adopting flexible regulatory policies that align with international standards. They affirmed that this cooperation facilitates the availability of innovative products in the Egyptian market and enhances Egypt's position as a regional hub for pharmaceutical manufacturing and export in the region. They also committed to providing the latest pharmaceutical products from Janssen, Johnson & Johnson's pharmaceutical arm, to Egyptian patients, and expressed the company's pride in its partnership with the Egyptian Drug Authority, which provides a conducive environment for introducing the latest global innovations.
Attendees from the Egyptian Drug Authority included Dr. Rasha Ziada, Assistant Chairman for Professional Development and Capacity Building Affairs , Prof. Dr. Hanan Amin Rizk, Head of Central Administration of Pharmaceutical Products , Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access , and Dr. Hossam Abdullah, Associate to the Chairman for Market Support and Monitoring & General Manager of General Administration of Market Access and Business Continuity.
From Johnson & Johnson, the attendees included Dr. Ahmed El-Houfy, CEO of Johnson & Johnson and Chairman of the Board for the markets of Egypt, Jordan, Libya, Sudan, and Ethiopia; Dr. Hatem Dawoud, Manager of Market Support and Government Affairs; Dr. Sara Sedky, Scientific Office Manager; and Dr. Hossam El-Badry, Head of Import and Distribution at the company.
This comes within the framework of the Egyptian Drug Authority's keenness to open wider horizons for cooperation with major international companies, support innovation and training, and transfer expertise, thereby enhancing Egypt's position as a leading regional center in the pharmaceutical industries and supporting the state's efforts to achieve pharmaceutical security and develop the healthcare system in line with Egypt's Vision 2030.